All In MedTech

Device Trial Radar · NCT07279220

Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture

A Prospective, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Safety and Effectiveness of the Vascular Closure Device for Femoral Artery Hemostasis in Patients of Femoral Artery Puncture

Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

238

Planned (sponsor's estimate)

Start

Dec 29, 2025

Primary completion

Mar 2, 2026

Study completion May 15, 2026

Sponsor

Lead sponsor
Shanghai Bomaian Medical Technology Co., LtdNot on our public-company list
Sponsor type
Industry
First posted
Dec 12, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to verify the safety and effectiveness of the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture.

Conditions

  • Femoral Artery Puncture
  • Vascular Closure Device
  • Hemostasis

Interventions

  • Vascular Closure Device Manufactured by Shanghai Bomaian Medical Technology Co., Ltd.Device

    The test group will use the Vascular Closure Device manufactured by Shanghai Bomaian Medical Technology Co., Ltd. for femoral artery hemostasis in patients of femoral artery puncture

  • MynxGrip Vascular Closure Device Manufactured by Cordis US CorpDevice

    The control group will use MynxGrip Vascular Closure Device Manufactured by Cordis US Corp for femoral artery hemostasis in patients of femoral artery puncture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device Success RateTime frame: Intra-procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Army Medical University (PLA)

    Chongqing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.